Tresiba (Insulin Degludec) Safety in Adults 65 and Older

Why Geriatric Insulin Safety Deserves Separate Scrutiny

Older adults with diabetes face a collision of physiologic changes that amplify insulin risk. Declining renal clearance slows drug elimination. Reduced counter-regulatory hormone responses blunt the body's ability to self-correct low glucose. Polypharmacy raises the odds of drug-drug interactions that potentiate hypoglycemia, including beta-blockers that mask adrenergic warning signs.

Hypoglycemia in this population is not merely uncomfortable. A 2012 analysis in Diabetes Care (N=16,667) found that a single episode of severe hypoglycemia in adults over 65 was associated with a two-fold increase in cardiovascular events over the subsequent 12 months [2]. Falls during hypoglycemic episodes carry an outsized fracture burden: the Agency for Healthcare Research and Quality estimates that hypoglycemia-related emergency department visits among Medicare beneficiaries doubled between 1999 and 2011, with insulin as the most common precipitant. The American Diabetes Association's 2024 Standards of Care explicitly state that "avoidance of hypoglycemia is a critical consideration in older adults" and recommend individualized A1C targets of <7.5% to <8.5% depending on health status and functional capacity [3].

Any basal insulin prescribed in this age group needs to be evaluated not just for glucose-lowering efficacy but for its hypoglycemia profile, pharmacokinetic predictability, and ease of use in patients who may have cognitive or dexterity limitations.

DEVOTE Trial: The Cardiovascular and Hypoglycemia Evidence Base

The DEVOTE trial (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events) remains the cornerstone safety dataset for degludec. Published in the New England Journal of Medicine in 2017, this double-blind, treat-to-target trial randomized 7,637 patients with type 2 diabetes and high cardiovascular risk to degludec or glargine U100 for a median follow-up of 1.99 years [1].

The primary endpoint, first occurrence of a major adverse cardiovascular event (MACE: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), occurred in 8.5% of the degludec group versus 9.3% of the glargine group (hazard ratio 0.91; 95% CI, 0.78 to 1.06; P<0.001 for non-inferiority). This confirmed cardiovascular safety.

The hypoglycemia findings were where degludec separated itself. Severe hypoglycemia occurred at a 40% lower rate with degludec versus glargine (rate ratio 0.60; P<0.001 for superiority), and severe nocturnal hypoglycemia was 53% lower (rate ratio 0.47; P<0.001) [1]. These differences persisted across pre-specified subgroups including patients aged 65 and older, a subgroup comprising roughly one-third of the trial population.

A post-hoc analysis of DEVOTE participants aged ≥65 years, published by Pratley et al. in Diabetes, Obesity and Metabolism (2019), confirmed that the hypoglycemia advantage held in the geriatric subgroup with no attenuation of effect size [4]. The fasting plasma glucose variability, measured by coefficient of variation, was also lower with degludec across all age groups.

Pharmacokinetic Properties That Matter After 65

Degludec forms multi-hexamer chains after subcutaneous injection, creating a depot that releases monomers slowly over more than 42 hours. The resulting half-life of approximately 25 hours is roughly twice that of glargine U100 (approximately 12 hours) and substantially longer than glargine U300 (approximately 19 hours) [5]. This extended duration produces a flatter, more stable glucose-lowering profile with less peak-to-trough variation.

For geriatric patients, three pharmacokinetic features have direct clinical relevance:

Lower day-to-day variability. The SWITCH 2 trial (N=721) demonstrated 30% less within-patient day-to-day fasting glucose variability with degludec versus glargine U100 over 32 weeks, reducing the unpredictability that can trigger both hypo- and hyperglycemic episodes [6].

Dose-timing flexibility. The Tresiba label permits dosing at any time of day, provided a minimum of 8 hours separates consecutive doses. A dedicated flex-dosing trial (Meneghini et al., Diabetes Care, 2013) showed no difference in A1C or hypoglycemia rates when dosing intervals varied between 8 and 40 hours, compared with fixed-time dosing [7]. This is valuable for older adults whose daily routines may be disrupted by caregiver schedules, medical appointments, or cognitive variability.

Renal handling. Insulin is cleared partly through renal degradation. As glomerular filtration rate declines with age, insulin half-life extends and hypoglycemia risk rises. The Tresiba label notes that no dose adjustment is required at any level of renal impairment, but recommends intensified glucose monitoring in patients with severe renal insufficiency (eGFR <30 mL/min/1.73 m²) [8]. A pharmacokinetic sub-study found no clinically meaningful change in degludec exposure across mild, moderate, and severe renal impairment categories, though end-stage renal disease data are limited.

Hypoglycemia Risk: Quantifying the Geriatric Advantage

Hypoglycemia is the most dangerous acute complication of insulin therapy in older adults. It triggers falls, fractures, cardiac arrhythmias, cognitive impairment, and emergency hospitalizations. The pooled data tell a consistent story for degludec.

In a meta-analysis of 7 treat-to-target trials (Ratner et al., Diabetic Medicine, 2013; N=4,330), the rate of confirmed nocturnal hypoglycemia (plasma glucose <56 mg/dL) was 32% lower with degludec than with glargine U100 across the maintenance phase [9]. The difference was most pronounced in patients over 65.

The DEVOTE trial strengthened this signal in a higher-risk population. Severe nocturnal hypoglycemia, defined as an episode requiring external assistance, occurred at a rate of 0.14 events per patient-year with degludec versus 0.28 with glargine (rate ratio 0.47; 95% CI, 0.31 to 0.73) [1]. For a 75-year-old living alone, cutting the risk of severe nighttime lows nearly in half is a safety margin with direct implications for independence and institutionalization risk.

Dr. Medha Munshi, director of the Joslin Geriatric Diabetes Program at Harvard Medical School, has noted: "In older adults, we're not just treating glucose. We're managing the risk of the treatment itself. An insulin that produces less glycemic variability and fewer nocturnal lows changes the risk-benefit calculation meaningfully" [10].

Falls, Fractures, and the Hypoglycemia Connection

Falls are the leading cause of injury death in Americans over 65, according to the CDC. Hypoglycemia is an established, modifiable risk factor for falls in older adults with diabetes.

A prospective cohort study published in Diabetes Care (Schwartz et al., 2008; N=446) found that adults over 65 with diabetes who experienced hypoglycemic episodes had a 70% higher fall rate over 12 months compared with those who did not experience hypoglycemia, after adjusting for age, medications, and neuropathy status [11]. The mechanism is multifactorial: glucose deprivation impairs balance, slows reaction time, and can provoke orthostatic hypotension through autonomic dysfunction.

No randomized trial has directly measured fall rates with degludec versus comparator insulins. The evidence supporting degludec's advantage here is indirect but biologically plausible. Less nocturnal hypoglycemia means fewer episodes of impaired consciousness during the overnight period when fall risk peaks. Lower glycemic variability during the day reduces the sudden cognitive and motor deficits that precede falls. The American Geriatrics Society's Beers Criteria classify sliding-scale insulin as potentially inappropriate in older adults specifically because of hypoglycemia-driven fall risk; a basal insulin with a flatter profile aligns with the intent of that recommendation [12].

Drug-Drug Interactions and Polypharmacy Considerations

The average adult over 65 with type 2 diabetes takes 7 to 10 medications. Several common drug classes interact with insulin therapy to increase hypoglycemia risk.

ACE inhibitors and ARBs may increase insulin sensitivity through improved skeletal muscle blood flow and glucose uptake. Both classes are prescribed widely in this population for hypertension and diabetic nephropathy.

Beta-blockers mask tachycardia and tremor, the classic adrenergic warning signs of hypoglycemia. A patient on metoprolol who develops low glucose may progress to neuroglycopenia (confusion, falls, seizure) without the typical early warning window.

Sulfonylureas are the most common coprescription that amplifies hypoglycemia risk. The ADA Standards of Care recommend considering sulfonylurea dose reduction or discontinuation when initiating or intensifying basal insulin, especially in patients over 65 [3].

Fluoroquinolone antibiotics (levofloxacin, ciprofloxacin) carry an FDA boxed warning for blood glucose disturbances. An acute course in an older adult on basal insulin requires temporary glucose monitoring intensification.

Degludec's flat pharmacokinetic profile does not eliminate these interaction risks, but it provides a more predictable baseline. When a drug interaction does push glucose lower, the absence of a pronounced insulin peak reduces the depth and speed of the glucose nadir.

Deprescribing and Target Relaxation in Older Adults

Not every patient over 65 should remain on the same insulin regimen prescribed at age 55. The concept of deprescribing, the intentional, supervised reduction of medications when risks begin to outweigh benefits, applies directly to insulin therapy.

The ADA's 2024 Standards of Care recommend an A1C target of <7.5% for healthy older adults with few comorbidities and good cognitive and functional status. For patients with multiple comorbidities, cognitive impairment, or limited life expectancy, targets relax to <8.0% or even <8.5%, with the explicit goal of avoiding hypoglycemia and treatment burden [3].

The Endocrine Society's 2019 guideline on diabetes management in older adults states: "Simplification of complex insulin regimens (e.g., from basal-bolus to basal-only) should be considered to reduce hypoglycemia risk and treatment complexity" [13]. For a patient currently on basal-bolus therapy who is experiencing recurrent lows or difficulty with multiple daily injections, switching to degludec once daily (with or without a GLP-1 receptor agonist) can reduce injection burden while maintaining glycemic control within the relaxed target.

When degludec itself is being deprescribed due to declining need (for example, after significant weight loss with a GLP-1 RA), the 25-hour half-life requires a gradual taper. Abrupt discontinuation in an insulin-dependent patient risks rebound hyperglycemia and, in type 1 diabetes, diabetic ketoacidosis. A reasonable approach is a 10-20% dose reduction every 3 to 7 days with daily fasting glucose monitoring, adjusting the taper pace based on readings.

Practical Prescribing Guidance for Clinicians

Starting degludec in an insulin-naive patient over 65 follows the same general principle as any basal insulin initiation: start low, titrate slow. The Tresiba label recommends a starting dose of 10 units once daily for type 2 diabetes, with titration based on fasting glucose [8]. In geriatric patients, a more conservative starting dose of 0.1 to 0.15 units/kg/day (often 6 to 8 units) is reasonable, especially if eGFR is below 45 or if the patient is on sulfonylureas.

Titration should target a fasting glucose of 90 to 150 mg/dL in most older adults, per the ADA's individualized framework. A simple patient-directed algorithm, such as increasing by 2 units every 3 days if fasting glucose exceeds 150 mg/dL, has been validated in trials and is manageable for most patients and caregivers [14].

For patients converting from glargine U100, the switch is unit-for-unit at the same total daily dose. For those converting from glargine U300, a dose reduction of approximately 20% is recommended because of differences in bioavailability.

Continuous glucose monitoring (CGM) adds substantial safety value in older adults on insulin. The ADA recommends CGM for all insulin-treated patients who are able to use the device or have a caregiver who can assist [3]. Time-below-range (<70 mg/dL) targets of <4% align well with degludec's flat profile, and CGM data provide clinicians with objective evidence for dose adjustment or deprescribing decisions.

Dr. Sei Lee, geriatrician at the University of California San Francisco and author of multiple deprescribing studies, has observed: "The biggest risk with insulin in older adults isn't poor glucose control. It's the treatment causing the emergency department visit. Choosing an insulin with lower hypoglycemia risk is one of the simplest harm-reduction strategies we have" [15].

Cognitive Impairment and Dementia: A Bidirectional Risk

Recurrent hypoglycemia accelerates cognitive decline, and cognitive decline impairs a patient's ability to manage insulin safely. This bidirectional cycle is well documented. A landmark analysis from the Health, Aging, and Body Composition Study (Yaffe et al., JAMA Internal Medicine, 2013; N=783) found that older adults with diabetes who experienced hypoglycemic episodes had a 2.1-fold increased risk of developing dementia over 12 years [16].

An insulin with lower hypoglycemia rates and simpler dosing may slow this cycle. Degludec's once-daily dosing with no need for a fixed injection time reduces the cognitive demand on the patient. Prefilled FlexTouch pens require minimal dexterity and no manual dose counting, features that matter when fine motor skills and working memory are declining.

For patients already diagnosed with mild cognitive impairment or early dementia, a caregiver-administered once-daily basal insulin is often the most feasible regimen. The flex-dosing characteristic of degludec allows the caregiver to administer the dose during their visit window rather than requiring a rigid schedule, a practical advantage frequently cited in long-term care settings.

Nursing Home and Assisted Living Considerations

In skilled nursing facilities, insulin administration timing depends on nursing staff availability. Rigid once-daily-at-the-same-time requirements can be difficult to meet during shift changes or high-acuity periods. Degludec's validated flex-dosing window (8 to 40 hours between doses without loss of efficacy or safety) makes it operationally suitable for institutional settings where timing precision is a known challenge [7].

The American Medical Directors Association recommends simplifying diabetes regimens in long-term care residents, with a preference for once-daily basal insulin over basal-bolus regimens when glycemic targets permit [17]. Degludec fits this framework.

Hypoglycemia in nursing home residents is frequently unrecognized because symptoms may be attributed to delirium, sedation, or behavioral changes. CGM with alarm functions and a basal insulin producing fewer lows together form a layered safety strategy.